|
Market Closed -
Hong Kong S.E.
04:08:09 2026-09-17 EDT
|
5-day change | 1st Jan Change | ||
| 190.00 HKD | -4.23% |
|
-1.20% | +39.71% |
| 09-16 | Fujian Haixi Pharma Gets Positive Data from Two Trials of Macular Degeneration Drug | MT |
| 09-02 | Fujian Haixi Pharmaceuticals Files Phase IIa Trial Application for Eye Drug | MT |
| Market Cap | 12.78B 14.98B 1.91B 1.66B 1.57B 1.43B 2.67B 183B 2.69B 18.71B 7.23B 92.91B 7.17B 7.01B 298B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 12.78B 14.98B 1.91B 1.66B 1.57B 1.43B 2.67B 183B 2.69B 18.71B 7.23B 92.91B 7.17B 7.01B 298B | EV / Sales 2026 * |
17.7x | EV / Sales 2027 * | 15x |
| Free-Float |
29.66% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -4.23% | ||
| 1 week | -1.20% | ||
| Current month | -1.04% | ||
| 1 month | -7.23% | ||
| 3 months | +6.15% | ||
| 6 months | +32.40% | ||
| Current year | +39.71% |
| 1 week | 181.5 |  | 202 |
| 1 month | 181.5 | | 248 |
| Current year | 125.3 | | 302.4 |
| 1 year | 97.5 | | 302.4 |
| 3 years | 97.5 | | 302.4 |
| 5 years | 97.5 | | 302.4 |
| 10 years | 97.5 | | 302.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yan Feng
PRN | Corporate Officer/Principal | 51 | 2012-03-26 |
Xin Shan Kang
CEO | Chief Executive Officer | 55 | 2012-03-26 |
Jun Huan Zhang
DFI | Director of Finance/CFO | 56 | 2021-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Xin Shan Kang
CHM | Chairman | 55 | 2017-10-31 |
Yan Feng
BRD | Director/Board Member | 51 | 2017-10-31 |
Guang Ming Chen
BRD | Director/Board Member | 62 | 2023-09-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.23% | -1.20% | - | - | 1.99B | |
| +1.28% | +2.51% | +50.70% | +100.19% | 1,014B | |
| +1.10% | +1.18% | +53.13% | +67.37% | 644B | |
| +0.58% | +5.22% | +22.08% | +73.56% | 464B | |
| -0.36% | +3.88% | +39.78% | +38.21% | 354B | |
| +1.52% | +3.90% | +19.76% | +25.75% | 265B | |
| +2.41% | +6.68% | +9.54% | +13.60% | 253B | |
| +0.91% | -2.94% | +39.07% | +45.67% | 203B | |
| +2.48% | -3.31% | -22.21% | -58.09% | 186B | |
| +2.17% | +3.60% | +36.11% | +99.41% | 183B | |
| Average | +0.47% | +1.18% | +27.55% | +45.07% | 356.88B | |
| Weighted average by Cap. | +0.57% | +1.41% | +35.90% | +61.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 722M 846M 108M 93.75M 88.72M 80.53M 151M 10.34B 152M 1.06B 408M 5.25B 405M 396M 16.82B | 850M 996M 127M 110M 104M 94.81M 177M 12.18B 179M 1.24B 481M 6.18B 477M 466M 19.8B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-17 | HK$190.00 | -4.23% | 493,900 |
| 26-09-16 | HK$198.40 | +3.33% | 85,268 |
| 26-09-15 | HK$192.00 | +1.05% | 47,000 |
| 26-09-14 | HK$190.00 | -1.55% | 111,050 |
| 26-09-11 | HK$193.00 | +1.74% | 147,650 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
162.41CNY
Average target price
251.05CNY
Spread / Average Target
+54.58%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 2637 Stock
Select your edition
All financial news and data tailored to specific country editions
